Maxygen's Next-Generation Interferon Alpha Enters Phase Ia Clinical Trial
Wed, 08 Nov 2006 08:00 AM EST
... Maxygen, Inc. (Nasdaq: MAXY) announced today that Roche has initiated a Phase Ia clinical trial in New Zealand to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of Maxy-alpha, a next-generation interferon alpha for the treatment of hepatitis C virus infection. [click link for full article] ...
Related Topics
- Clinical Trials
- Alpha Hydroxy Acid
- Alpha-1 Antitrypsin Deficiency
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Trypsin
- Tarceva
- Ribavirin and Interferon alfa-2b, recombinant
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Bevacizumab Injection
- Clinical Growth Charts
- Interferon Alfa-2a
- Lead
- Crohn's Disease
- Interferon Alfa-2b
- Pancreatic Cancer
- Interferon
- Patient Issues

Not Signed In -


